Vistagen Acquires Pherin Pharmaceuticals
December 21, 2022
Vistagen (Nasdaq: VTGN) will acquire Pherin Pharmaceuticals in an all-stock transaction (approximately 12.4 million shares plus nominal cash), giving Vistagen full ownership of Pherin's pherine drug pipeline and intellectual property. The deal eliminates future royalty and milestone obligations related to PH94B and PH10 and adds three early-stage pherine candidates to Vistagen's development portfolio.
- Buyers
- Vistagen
- Targets
- Pherin Pharmaceuticals, Inc.
- Sellers
- Pherin Pharmaceuticals' stockholders
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Grundium Acquires Visiopharm
May 25, 2026
AI & Machine Learning
Grundium announced it has acquired Visiopharm to create an integrated precision pathology platform that combines digital slide scanning with AI-driven pathology software. The combined offering is intended to support diagnostic laboratories, biopharmaceutical development, and research organizations with more scalable, cost-effective digital pathology workflows, including biomarker assessment and clinical research use cases.
-
InSphero AG Acquires PhenoVista Biosciences, Inc.
May 20, 2026
Healthcare Services
InSphero AG announced it has acquired PhenoVista Biosciences, Inc., a San Diego-based contract research organization specializing in high-content imaging and phenotypic assay technologies. The deal is intended to expand InSphero’s advanced 3D, cell-based assay and imaging capabilities and accelerate adoption of more predictive, human-relevant drug discovery and toxicology workflows.
-
Lupin Acquires VISUfarma from GHO Capital
September 29, 2025
Healthcare Services
Lupin Limited, through its wholly owned subsidiary Nanomi B.V., signed a definitive agreement to acquire VISUfarma B.V. from healthcare investor GHO Capital Partners LLP. The acquisition expands Lupin’s specialty ophthalmology franchise by adding a portfolio of 60+ branded eye health products and established commercial operations across major European markets.
-
Pfizer Completes Acquisition of Biohaven Pharmaceutical Holding Company Ltd.
October 3, 2022
Biotechnology
Pfizer completed its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC ODT (rimegepant). The all-cash transaction is valued at approximately $11.6 billion and makes Biohaven a wholly owned subsidiary of Pfizer.
-
Charles River Laboratories Acquires Vigene Biosciences
May 17, 2021
Biotechnology
Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.
-
Venn Life Sciences Acquires Kinesis Pharma
September 22, 2015
Healthcare Services
Dublin-based clinical research group Venn Life Sciences will acquire Netherlands-based Kinesis Pharma for an initial consideration of €3.6 million, with up to €6.5 million payable including performance-related earnouts. The acquisition expands Venn’s early-stage drug development consultancy capabilities (Kinesis has ~60 employees and a presence in Singapore) and is intended to drive cross-selling of downstream services.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.